Business Wire

ONCOCROSS

Share
Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine

Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.

Under this contract, the two companies will join research efforts to identify and verify development possibilities for new indications for the 'first-in-class' drug pipeline that JW Pharmaceutical is developing in the area of anticancer and regenerative medicine.

For this purpose, Oncocross’s proprietary AI platform RAPTOR AITM will be utilized. RAPTOR AITM is an AI drug development platform that screens the optimal or additional indications for drug candidates or existing drugs. The platform provides AI capabilities necessary for pharmaceutical companies' new drug development, resulting in higher accuracy, reduced cost, and shorter development time compared to traditional methods.

Previously, the two companies signed a joint research agreement to identify new indications for drug candidates in 2022. Through this joint research, JW Pharmaceutical has secured positive data on expanding an orphan disease indication for the new drug candidate and is establishing a follow-up development plan.

Having previously verified the RAPTOR AITM technology, JW Pharmaceutical once again expects to reduce the time required for new indication screening and increase the probability of success in clinical studies for the 'first-in-class' drug pipelines.

JW Pharmaceutical said, “The level of innovation we are focusing on requires high R&D capabilities and substantial costs and time to discover new drug candidates and indications,” adding, “We will continue to pursue diverse partnerships with innovative local and global biotech companies that possess new technologies such as Oncocross.”

Dr. Yirang Kim, CEO of Oncocross commented, "This follow-on collaboration is significant in the sense that the utility and commercial value of RAPTOR AITM has been recognized in the market.” He further added, “We will continue to do our best to set examples of collaboration between large pharmaceutical companies and biotech in the AI drug development field.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528528566/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis14.2.2025 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluviohas the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis1-3 There is a need for new treatment options for atopic dermatitis and prurigo nodularis to effectively relieve the signs and symptoms such as persistent itch, skin lesions and poor sleep quality4-8 Nemluviois the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis5,8-10 Nemluvio is the first monoclonal antibody in Galderma’s portfolio of innovative, science-based products, which span the full spectrum of the fast-growing dermatology market Galderma (SWX:G

City of Oulu: Finland’s Largest Hydrogen Refining Plant One Step Closer to Starting Sustainable Aviation Fuel Production13.2.2025 18:30:00 CET | Press release

French Verso Energy and City of Oulu sign co-operation agreement The City of Oulu, Finland, and French company Verso Energy have signed a co-operation agreement aiming to build a hydrogen processing plant in Oulu. Verso Energy intends to construct a plant with a yearly production capacity of 80 000 tonnes of e-SAF. The estimated value of the project is €1.4 billion, and it is expected to create 250 jobs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213216649/en/ The City of Oulu, Finland, and French company Verso Energy have signed a co-operation agreement at the Northern Power forum aiming to build a hydrogen processing plant in Oulu. Signing the agreement strengthens the City of Oulu’s status as a key hydrogen hub in the Nordics. Verso Energy’s plant in the port area of Oulu will be the largest of its kind in Finland so far. In the picture from left to right: Ari Alatossava, Mayor of Oulu, Antoine Huard, CEO of Verso

Net Profit of Estithmar Holding Increases by 20% to QAR 422 Million, Revenues Rise by 44% to Reach QAR 4.2 Billion13.2.2025 18:13:00 CET | Press release

Financial Results Announcement for the FY 2024 Estithmar Holding Q.P.S.C. announced its financial results for the year ended December 31, 2024, reporting a 44% increase in revenues, reaching QAR 4.2 billion, compared to QAR 2.9 billion in 2023. The gross profits of the company reached QAR 1 billion, up from QAR 801 million in 2023, reflecting a 27% increase. The company also achieved earnings before interest, tax, depreciation, and amortization (EBITDA) of QAR 742 million. The results showed a 20% rise in the company’s net profit compared to 2023, reaching QAR 422 million. Earnings per share also increased by 17% from 2023, reaching QAR 0.119 per share. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213715874/en/ Net Profit of Estithmar Holding Increases by 20% to QAR 422 Million, Revenues Rise by 44% to Reach QAR 4.2 Billion (Graphic: AETOSWire) The 20% growth in net profit is attributed to the increase in the company’s

UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation13.2.2025 18:12:00 CET | Press release

Initial advanced air mobility (AAM) regulations under development for the UAE GCAA and ATRC entities – TII and ASPIRE collaborate on technical expertise and airspace management The UAE has taken a bold step towards redefining urban transportation with the commencement of air corridor mapping and regulatory framework development for piloted and autonomous air taxis and cargo drones. This transformative initiative marks a major leap forward in the nation’s mission to lead the future of mobility. Through a strategic partnership between the General Civil Aviation Authority (GCAA) and the Advanced Technology Research Council (ATRC) entities—Technology Innovation Institute (TII) and ASPIRE—the UAE is on track to reshape the way people and goods move through urban spaces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213996930/en/ UAE Begins Mapping Air Corridors for Air Taxis and Cargo Drones to Transform Urban Transportation

Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador13.2.2025 18:00:00 CET | Press release

Amazfit becomes Thomas’ first Smartwatch Partner Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213824479/en/ Five-time Olympic Medalist and fashion icon, Gabby Thomas, is the latest ambassador to join Amazfit's growing roster of elite athletes. (Graphic: Business Wire) As the 200m, 4x100m and 4x400m gold medalist, Thomas left the 2024 Paris Olympics as the most decorated U.S. track and field athlete at t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye